Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$87.73 USD

87.73
4,499,207

-1.77 (-1.98%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $87.73 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (155 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Q1 Earnings Top Estimates, Margins Up

Increased adoption of the PASCAL platform along with continued strength in the HemoSphere monitoring platform drove Edwards Lifesciences' (EW) Q1 revenues.

Edwards Lifesciences (EW) Beats Q1 Earnings and Revenue Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.45% and 2.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Humana (HUM) Gears Up For Q1 Earnings: What's in the Cards?

Humana's (HUM) first-quarter earnings are likely to reflect the impacts of elevated costs related to investments in technology advancements, partly offset by higher premiums in the Retail segment and sound membership growth.

Edwards Lifesciences (EW) to Post Q1 Earnings: What's in Store?

Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) first-quarter performance.

Edwards Lifesciences (EW) Earnings Expected to Grow: Should You Buy?

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Gains But Lags Market: What You Should Know

Edwards Lifesciences (EW) closed at $121.91 in the latest trading session, marking a +0.89% move from the prior day.

Abiomed (ABMD) Announces Successful Usage of Impella in Japan

Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.

Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.

AmerisourceBergen's (ABC) Venture Capital Fund to Aid Healthcare

AmerisourceBergen's (ABC) new corporate venture capital fund to help emerging healthcare startup companies change healthcare for people and animals globally.

Here's Why You Should Retain West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes

Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.

PerkinElmer (PKI) Boosts In Vivo Imaging Profile With New System

PerkinElmer's (PKI) launch of the Vega imaging system is likely to help the company expand its in vivo imaging portfolio.

PerkinElmer's (PKI) New Assay Kits to Detect CHO HCP Impurities

PerkinElmer (PKI) launches ready-to-use HTRF and AlphaLISA no-wash assay kits to quickly identify and quantify CHO HCP impurities.

Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint

Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.

Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome

Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.

Edwards Lifesciences (EW) Stock Moves -0.05%: What You Should Know

In the latest trading session, Edwards Lifesciences (EW) closed at $120.22, marking a -0.05% move from the previous day.

HOLX vs. EW: Which Stock Is the Better Value Option?

HOLX vs. EW: Which Stock Is the Better Value Option?

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Shockwave Medical's (SWAV) New Launch to Lower IVL Treatment Time

Shockwave Medical's (SWAV) latest global commercial launch is expected to serve a more diverse patient pool.

DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management

DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.

Strength Seen in Alphatec (ATEC): Can Its 12.1% Jump Turn into More Strength?

Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve

Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.

Edwards Lifesciences (EW) Up 7.5% Since Q4 Earnings Release

Edwards Lifesciences' (EW) stock rallies on impressive fourth-quarter performance and bullish 2022 guidance.